Show simple item record

dc.creatorSinha, Pranay
dc.creatorMostaghim, Anahita
dc.creatorBielick, Catherine G.
dc.creatorMcLaughlin, Angela
dc.creatorHamer, Davidson H.
dc.creatorWetzler, Lee M.
dc.creatorBhadelia, Nahid
dc.creatorFagan, Maura A.
dc.creatorLinas, Benjamin P.
dc.creatorAssoumou, Sabrina A.
dc.creatorIeong, Michael H.
dc.creatorLin, Nina H.
dc.creatorCooper, Ellen R.
dc.creatorBrade, Karrine D.
dc.creatorWhite, Laura F.
dc.creatorBarlam, Tamar F.
dc.creatorSagar, Manish
dc.date.accessioned2020-09-22T20:07:10Z
dc.date.available2020-09-22T20:07:10Z
dc.date.created2020
dc.identifier.issn1201-9712spa
dc.identifier.otherhttps://doi.org/10.1016/j.ijid.2020.07.023spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/13606
dc.description.abstractObjective: The aim of this observational study was to determine the optimal timing of interleukin-6 receptor inhibitor (IL6ri) administration for coronavirus disease 2019 (COVID-19). Methods: Patients with COVID-19 were given an IL6ri (sarilumab or tocilizumab) based on iteratively reviewed guidelines. IL6ri were initially reserved for critically ill patients, but after review, treatment was liberalized to patients with lower oxygen requirements. Patients were divided into two groups: those requiring 45% fraction of inspired oxygen (FiO2) (termed stage IIB) and those requiring >45% FiO2 (termed stage III) at the time of IL6ri administration. The main outcomes were all-cause mortality, discharge alive from hospital, and extubation. Results: A total of 255 COVID-19 patients were treated with IL6ri (149 stage IIB and 106 stage III). Patients treated in stage IIB had lower mortality than those treated in stage III (adjusted hazard ratio (aHR) 0.24, 95% confidence interval (CI) 0.08–0.74). Overall, 218 (85.5%) patients were discharged alive. Patients treated in stage IIB were more likely to be discharged (aHR 1.43, 95% CI 1.06–1.93) and were less likely to be intubated (aHR 0.43, 95% CI 0.24–0.79). Conclusions: IL6ri administration prior to >45% FiO2 requirement was associated with improved COVID19 outcomes. This can guide clinical management pending results from randomized controlled trials.spa
dc.format.extent6 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherInternational Journal of Infectious Diseasesspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCOVID-19spa
dc.subjectTocilizumabspa
dc.subjectSarilumabspa
dc.subjectInterleukin-6 inhibitorsspa
dc.subjectCytokine release syndromespa
dc.titleEarly administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased dischargespa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAbierto (Texto Completo)spa
dc.identifier.doihttps://doi.org/10.1016/j.ijid.2020.07.023spa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record